Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Haemdates Syrup
- Development stage
- Phase 4
- Lead developer
- Kaiser Drugs
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Haemdates is an oral haematinic syrup developed and marketed by Kaiser Pharmaceutical, an Indian branded generic company. It is primarily used as a nutritional supplement for the treatment and prevention of anemia and various vitamin deficiencies. The formulation contains Vitamin B12 as a key active ingredient and is closely associated with the Haemdates-XT brand, which typically incorporates folic acid. As a blood-building agent, it supports essential biological processes such as erythropoiesis and DNA synthesis. The product is commercially available in India in 150ml to 200ml syrup bottles and is classified as a small molecule nutritional supplement.
- Brand names
- Haemdates SyrupHaemdates-XT Syrup
- Other names
- Haemdates
02
Targets
DHFR (Dihydrofolate reductase)MTR (Methionine synthase)
Beyond the preview
Go deeper on Haemdates Syrup.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Haemdates Syrup.